1368 A novel bispecific BCA356 targeting tumour antigen CAIX conjugated to an attenuated IL12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity
1368 A novel bispecific BCA356 targeting tumour antigen CAIX conjugated to an attenuated IL12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity
PDF